GlassScriptPhysician profile
Ryan M Quarless
NPI 1528016797
$1,263.85
in general payments reported to CMS, 2019-2025
23 companies · $183 in 2025
The $183 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $181 · 2022: $237 · 2023: $384 · 2024: $280 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $846.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $246.10 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Gilead Sciences, INC. | $197.19 | 2021-2024 | Veklury |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.61 | 2021-2025 | Ofev |
| Mylan Specialty L.P. | $86.41 | 2023-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $86.17 | 2024-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $83.96 | 2022-2025 | Airsupra, Breztri, Fasenra |
| Baxter Healthcare | $59.42 | 2023 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| United Therapeutics Corporation | $50.03 | 2022-2024 | Tyvaso |
| Genzyme Corporation | $35.08 | 2025 | |
| Merck Sharp & Dohme LLC | $29.74 | 2023-2024 | Dificid, Zerbaxa, Recarbrio |
| Mallinckrodt Hospital Products INC. | $26.21 | 2021 | |
| Csl Behring | $24.76 | 2024 | Hizentra |
| Actelion Pharmaceuticals US, INC. | $23.67 | 2024 | Opsumit, Uptravi |
| Pfizer INC. | $20.26 | 2025 | |
| La Jolla Pharmaceutical Company | $19.44 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $17.46 | 2025 | Yupelri |
| Novartis Pharmaceuticals Corporation | $16.53 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.21 | 2021 | |
| Insmed, INC. | $15.64 | 2023 | Arikayce |
| Shionogi INC | $15.18 | 2023 | Fetroja |
| E.R. Squibb & Sons, L.L.C. | $14.53 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.40 | 2022 | |
| Electromed, INC. | $13.85 | 2024 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Quarless listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.